



Pulmonary Disease, Animal Modeling, & Vaccine Development

Tori Baxter, DVM, PhD

Introduction to Pathology of Disease

NC A&T Biol 342, NCCU Special Course

October 7, 2021



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

What Are We Going to Cover Today?

- Normal lung anatomy and histology
- Evaluating lung function
- Pathological changes to the lung
- Using animal models to study respiratory disease
- Vaccine development





What Are We Going to Cover Today?


- **Normal lung anatomy and histology**
- Evaluating lung function
- Pathological changes to the lung
- Using animal models to study respiratory disease
- Vaccine development



Normal Lung Anatomy



Bronchus




meddean.luc.edu




THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

GAS EXCHANGE IN HUMANS




ALVEOLUS GAS EXCHANGE




www.pedilung.com



Alveoli



meddean.luc.edu



What Are We Going to Cover Today?

- Normal lung anatomy and histology
- **Evaluating lung function**
- Pathological changes to the lung
- Using animal models to study respiratory disease
- Vaccine development



Pulmonary Function Tests


- **Spirometry** – measures the rate of air flow and estimates lung size
- **Plethysmography** – measures lung volume changes
- **Lung Diffusion Capacity** – assesses how well oxygen gets into blood
- **Pulse Oximetry** – estimates oxygen levels in blood
- **Arterial Blood Gas** – directly measures levels of gases in blood
- **Fractional Exhaled Nitric Oxide** – measures how much nitric oxide is in exhaled air

Modeling Pulmonary Function Tests



Spirometry



Plethysmography



Pulse Oximetry




What Are We Going to Cover Today?

- Normal lung anatomy and histology
- Evaluating lung function
- **Pathological changes to the lung**
- Using animal models to study respiratory disease
- Vaccine development




Asthma

- Clinical:
 - Airway hyper-responsiveness
 - Triggers: antigens, exercise, drugs, infections, stress
 - Acute, usually reversible diffuse bronchial narrowing
 - Wheezing, dyspnea
- Pathology:
 - Edema, smooth muscle thickening, basement membrane thickening, mucous cell hyperplasia, increased submucosal eosinophils, thickened intraluminal mucus




Aspiration

- Clinical:
 - Children - foreign bodies
 - Adults - gastric acid, food, foreign bodies
 - Lipids in nasal drops
- Pathology:
 - Foreign material → foreign body giant cell reaction with exogenous material



Emphysema

- Clinical:
 - Increased elastase activity
 - Cigarette smoking
 - Inherited α 1-antitrypsin deficiency
- Pathology:
 - Dilation of distal airspaces with septal destruction






Lung Infections

- Types of inflammatory response
- Bacterial pneumonia
- Viral
- Mycobacteria
- Fungal




Types of Inflammatory Responses

- Neutrophils
 - Usually bacterial
 - Usually in alveoli
- Lymphocytes
 - Usually viral
 - Usually in interstitium / septae
- Granulomatous inflammation
 - Usually mycobacterial or fungal




Bacterial Pneumonia

- Most bacteria are normal inhabitants of the nasopharynx or oropharynx
- Reach alveoli by
 - Aspiration (most)
 - Inhalation
 - Hematogenous seeding
 - Direct spread from adjacent site (rare)
- Pneumococcal pneumonia
 - *Streptococcus pneumoniae*
 - Pulmonary edema, bacterial proliferation, neutrophils





Viral Pneumonia

- Immune compromised
 - HIV, organ transplants
- Infants may get CMV
- Lymphocytes in the interstitium
- Distinct cytologic inclusions for some viral infections





Tuberculosis

- *Mycobacterium tuberculosis*
- Infection by inhalation of aerosolized droplets containing organisms
- Caseous granulomatous inflammation results
- 90% of primary exposures asymptomatic



Fungal Pneumonia

- Fungi are ubiquitous in soil and air
- Most exposure fails to produce infection
 - Body temperature arrests growth
 - Phagocytosis by neutrophils and macrophages
 - Risks: chemo, steroids, T cell deficiencies
- Usually granulomatous inflammation
- Silver stains demonstrate organisms




What Are We Going to Cover Today?

- Normal lung anatomy and histology
- Evaluating lung function
- Pathological changes to the lung
- **Using animal models to study respiratory disease**
- Vaccine development




COVID-19 in Humans



- **Flu-like illness:** fever, chills, fatigue, cough, congestion, shortness of breath, sore throat, body aches, headache, diarrhea
- **Loss of taste or smell**
- **Severe disease manifestations:** pneumonia, respiratory failure, sepsis, multi-organ failure, cardiomyopathy, acute kidney injury, stroke



Lung Pathology in COVID-19 Patients




Polak et al, *Mod Pathol*, 2020



Scendoni et al, *Diag Pathol*, 2020

- Atypia and detachment of type II pneumocytes
- Hyaline membranes
- Interstitial inflammation
- Epithelial denudation
- Hyaline thrombi
- Fibrinous pneumonia
- Edema
- Intra-alveolar fibroelastosis

SARS-CoV-2 Host Range



Hamsters as an Animal Model for SARS-CoV-2 Infection



- **Clinical Signs:**

- Fever
- Dyspnea
- Weight loss



- **Tissue Tropism:**

- Upper and lower airways
- Nasal and bronchiolar epithelium



- **Potential Applications:**

- Pathogenesis
- Transmission dynamics
- Vaccines and therapeutics

Nasal Epithelium – 2 DPI



Lung Parenchyma – 5 DPI



Ferrets as an Animal Model for SARS-CoV-2 Infection



- **Clinical Signs:**

- Fever
- Appetite loss



4 DPI

- **Tissue Tropism:**



- Upper respiratory tract
- GI tract

- **Potential Applications:**

- Vaccines and anti-virals
- Transmission dynamics



SARS-CoV-2 Infection of Mink



Macaques as an Animal Model for SARS-CoV-2 Infection



- **Clinical Signs:**

- Changes to respiratory pattern
- Fever
- Weight loss




- **Tissue Tropism:**

- Lung
- Lymphoid Tissue
- GI Tract

- **Potential Applications:**

- Pathogenesis
- Vaccines and therapeutics
- Chronic effects

3 DPI




Advantages to Using Mice



- Similar anatomy, physiology, and genetics to humans
- Relatively cost effective
- Genetically modifiable
- Small and easy to house
- Short gestation time and lifespan
- Quick maturation
- Good array of reagents for research



Barriers to Using Mice to Study COVID-19



Wiese et al, JCP, 2021



Arce and Costoya, C&MI, 2021



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

Mouse Model Approaches

- Transgenic Mice
- Viral Vector-Mediated Sensitization
- Humanized Mice
- Mouse-Adapted SARS-CoV-2 Strains



K18-hACE2 Mice

- Transgenic mice with human ACE2 constitutively expressed in epithelial cells
- Can use human clinical SARS-CoV-2 isolates

- **Clinical Signs:**



- Weight loss
- Hunched posture
- Mortality

- **Tissue Tropism:**

- Lung
- Brain
- Systemic replication


- **Potential Applications:**

- Pathogenesis
- Vaccines and therapeutics





Ad5-hACE2 Mice

- Exogenous delivery of human ACE2 with a replication-deficient adenovirus under control of a CMV promoter
- Can use human clinical SARS-CoV-2 isolates
- **Clinical Signs:**
 - Weight loss
 - Hunched posture
- **Tissue Tropism:**
 - Lung
- **Potential Applications:**
 - Pathogenesis
 - Vaccines and therapeutics




Humanized Mice


- Subcutaneous implantation of human lung tissue into the backs of immunodeficient mice
- Can use human clinical SARS-CoV-2 isolates
- **Clinical Signs:**
 - None?
- **Tissue Tropism:**
 - Human Lung Implant
- **Potential Applications:**
 - Viral Replication Kinetics
 - Lung Pathology
 - Human Immune Response
 - Prophylactics and Therapeutics






Mouse Adaptation of SARS-CoV-2




**Original
SARS-CoV-2**





**Q498Y/P499T
SARS-CoV-2-MA**



2 DPI



4 DPI




Dinno *et al*, *Nature* 2020




THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL

Mouse Adaptation of SARS-CoV-2




Mouse Adaptation of SARS-CoV-2



**Pathogenic
SARS-CoV-MA10**

Mutation	Gene	Coding Change
C9438U	nsp4	T285I
A11847G	nsp7	K2R
A12159G	nsp8	E23G
C23039A	Spike	Q493K
U27221C	ORF6	F7S

Leist et al, Cell 2020



Lung Pathology Scoring


ATS Acute Lung Injury Score (2011 Matute-Bello et al.)

	Neutrophils in the alveolar space	Neutrophils in the interstitial space	Hyaline membranes	Proteinaceous debris filling the airspaces	Alveolar septal thickening relative to mock
0	None	None	None	None	< 2X
1	1-5	1-5	1	1	2X - 4X
2	>5	>5	>1	>1	>4X


M.E. Schmidt DAD Score (Schmidt et al. 2018)

1	Absence of cellular sloughing and necrosis
2	Uncommon solitary cell sloughing and necrosis (1-2 spots)
3	Multifocal cellular (3+) sloughing with uncommon septal wall hyalinization
4	Multifocal cellular sloughing (>75% field) with common and/or prominent hyaline membranes


Mock-Infected



Moderate Lung Injury




Severe Lung Injury




Other Pathological Changes


Perivascular edema




Loss of interstitial architecture




Extensive hyaline membranes




Perivascular cuffs



Early regenerative changes



Pulmonary adenoma




What Are We Going to Cover Today?

- Normal lung anatomy and histology
- Evaluating lung function
- Pathological changes to the lung
- Using animal models to study respiratory disease
- **Vaccine development**




Vaccine Development Process

- Preclinical Studies
- Clinical Trials
 - Phase I
 - Safety, immunogenicity, dosage
 - Young, healthy adult volunteers
 - Phase II
 - Target population
 - Placebo group
 - Phase III
 - Efficacy studies
 - Large diverse populations
 - Placebo group





Immune Responses to Vaccines

- Humeral Response
 - Antibody
- Cellular Reponses
 - CD4+ T cells
 - CD8+ T cells
- Ideally a vaccine elicits both a strong humeral response and a strong cellular response




Vaccine Components

- Antigen
- Preservatives
- Stabilizers
- Surfactants
- Residuals
- Diluent
- Adjuvant




Vaccine Approaches

- Live attenuated
- Inactivated
- Viral vectored
- Protein subunit
- mRNA




Live Attenuated Vaccines

- Weakened version of the actual virus
- Present all target antigens
- Tend to elicit strong immune responses
- Examples
 - MMR
 - Chickenpox
 - **COVID:** Codagenix, Indian Immunologicals




Inactivated Vaccines

- Uses the whole virus after it has been killed with heat or chemicals
- Contain all antigens but not necessarily in native form
- Tend to primarily elicit antibody responses
- Often include adjuvants
- Examples
 - Polio
 - Rabies virus
 - **COVID:** Sinovac, Sinopharm




Viral Vectored Vaccines

- Uses the backbone of a virus to deliver viral genes
- Present specific antigens
- Tend to elicit strong immune responses
- Examples
 - Ebolavirus
 - Canine Distemper Virus
 - West Nile Virus (horses)
 - **COVID:** AstraZeneca, Johnson & Johnson




Protein Subunit Vaccines

- Uses a piece of a virus's protein
- Focuses on a small, important portion of the virus
- Tend to primarily elicit antibody responses
- Often include adjuvants
- Examples
 - Pertussis
 - Hepatitis B
 - HPV
 - **COVID:** Novavax



mRNA Vaccines

- Contains the coding portion of a virus protein
- Present specific antigens
- Tend to elicit strong immune responses (we think)
- Examples
 - **COVID:** Pfizer BioNTech, Moderna




What Are We Going to Cover Today?

- Normal lung anatomy and histology
- Evaluating lung function
- Pathological changes to the lung
- Using animal models to study respiratory disease
- Vaccine development



Any Questions?



“Don’t play with him, he is **Wild Type**.”

